Disease Rescue and Increased Lifespan in a Model of Cardiomyopathy and Muscular Dystrophy by Combined AAV Treatments

The BIO14.6 hamster is an excellent animal model for inherited cardiomyopathy, because of its lethal and well-documented course, due to a spontaneous deletion of delta-sarcoglycan gene promoter and first exon. The muscle disease is progressive and average lifespan is 11 months, because heart slowly dilates towards heart failure.Based on the ability of adeno-associated viral (AAV) vectors to transduce heart together with skeletal muscle following systemic administration, we delivered human delta-sarcoglycan cDNA into male BIO14.6 hamsters by testing different ages of injection, routes of administration and AAV serotypes. Body-wide restoration of delta-SG expression was associated with functional reconstitution of the sarcoglycan complex and with significant lowering of centralized nuclei and fibrosis in skeletal muscle. Motor ability and cardiac functions were completely rescued. However, BIO14.6 hamsters having less than 70% of fibers recovering sarcoglycan developed cardiomyopathy, even if the total rescued protein was normal. When we used serotype 2/8 in combination with serotype 2/1, lifespan was extended up to 22 months with sustained heart function improvement.Our data support multiple systemic administrations of AAV as a general therapeutic strategy for clinical trials in cardiomyopathies and muscle disorders

Worsening of Cardiomyopathy Using Deflazacort in an Animal Model Rescued by Gene Therapy

We have previously demonstrated that gene therapy can rescue the phenotype and extend lifespan in the delta-sarcoglycan deficient cardiomyopathic hamster. In patients with similar genetic defects, steroids have been largely used to slow down disease progression. Aim of our study was to evaluate the combined effects of steroid treatment and gene therapy on cardiac function. We injected the human delta-sarcoglycan cDNA by adeno-associated virus (AAV) 2/8 by a single intraperitoneal injection into BIO14.6 Syrian hamsters at ten days of age to rescue the phenotype. We then treated the hamsters with deflazacort. Treatment was administered to half of the hamsters that had received the AAV and the other hamsters without AAV, as well as to normal hamsters. Both horizontal and vertical activities were greatly enhanced by deflazacort in all groups. As in previous experiments, the AAV treatment alone was able to preserve the ejection fraction (70±7% EF). However, the EF value declined (52±14%) with a combination of AAV and deflazacort. This was similar with all the other groups of affected animals. We confirm that gene therapy improves cardiac function in the BIO14.6 hamsters. Our results suggest that deflazacort is ineffective and may also have a negative impact on the cardiomyopathy rescue, possibly by boosting motor activity. This is unexpected and may have significance in terms of the lifestyle recommendations for patients

D2-Dopaminergic Agonist Quinpirole and 8-Bromo-Camp have Opposite Effects on Goα Gtp-Binding Protein mRNA without Changing D2 Dopamine Receptor mRNA Levees in Striatal Neurones in Primary Culture

International audienceLong-term coordinated regulations (during development or by agonists and second messenger molecules) of the expression of mRNAs encoding D2-dopamine (DA) receptors and D2 receptor-linked Go alpha proteins have been studied by Northern blot analysis in mouse embryonic striatal neurones in primary culture. During the course of the cell culture, the levels of both mRNAs increased, in conjunction with the maturation of the neurones. When the preparation was treated with the D2-DA agonist quinpirole (5-15 hrs, 10(-4) M), which decreases cAMP in these neurones, the levels of Go alpha mRNAs were enhanced whereas that of the D2 mRNA remained unchanged. Conversely, the Go alpha mRNAs, but not the D2 mRNA, decreased when the neurones were exposed to 8-bromo-cAMP (16 hrs, 10(-6) M). It is concluded that, in these experimental conditions where neurones have not yet established their connexions, the longterm regulation of the membrane transmission of D2-DA signal might implicate mainly the Go alpha encoding gene